MedTrace Logo

Safety and Efficacy Comparator Trial of a New Drug Against Genital Herpes

NCT01658826 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 91

Last updated 2023-04-21

Study results available
· View outcomes & findings →

Summary

The aim of the study is to evaluate the safety and efficacy of "AIC316 (pritelivir)" 100 mg once daily compared to valacyclovir 500 mg once daily for the prevention of HSV-2 genital shedding.

Conditions

  • Genital Herpes

Interventions

DRUG

AIC316

100 mg oral administration

DRUG

Valacyclovir

500 mg oral administration

Sponsors & Collaborators

  • Medpace, Inc.

    collaborator INDUSTRY

  • AiCuris Anti-infective Cures AG

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-10-31
Primary Completion
2013-05-31
Completion
2013-07-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01658826 on ClinicalTrials.gov